Navigation Links
CytoSorbents to Report Q2 2014 Operating and Financial Results
Date:8/6/2014

MONMOUTH JUNCTION, N.J., Aug. 6, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report Q2 2014 financial results after the market close on Tuesday, August 12, 2014. 

CytoSorbents' management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q2 2014 and answer pre-submitted questions as time permits.

Conference Call Details:
Date: Tuesday, August 12, 2014
Time: 4:15 PM Eastern
Participant Dial-In: 913-312-1269
Live Presentation Webcast:  https://viavid.webcasts.com/starthere.jsp?ei=1041083

It is recommended that participants dial in approximately 10 minutes prior to the start of the call.  There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link:  https://viavid.webcasts.com/starthere.jsp?ei=1041083

An archived recording of the conference call will be available under the Investor Relations section of the Company's website at http://www.cytosorbents.com/invest.htm

Investors are encouraged to submit their questions in advance as soon as possible to Ms. Amy Vogel at avogel@cytosorbents.com

About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to modulate inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com/

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on March 31, 2014, which is available at http://www.sec.gov.

Please Click to Follow us on Facebook and Twitter

Logo - http://photos.prnewswire.com/prnh/20140408/MM00899LOGO


'/>"/>
SOURCE CytoSorbents Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. MedReps.com Report Highlights Power of Mobile Medical Sales Job Search
2. 2-EH Market & Linear Alkyl Benzene Industry – Global, China Regions Research Analysis Now Available at DeepResearchReports.com
3. PharmAthene Reports Second Quarter 2014 Financial And Operational Results
4. Origin Agritech Limited Reports Unaudited Third Quarter Financial Results For Three Months Ended June 30, 2014
5. Ammonium Bicarbonate Market in Internations & Chinese Regions Research Analysis Now Available at DeepResearchReports.com
6. Cambrex Reports Second Quarter 2014 Financial Results
7. Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com
8. BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014
9. Kidney Cancer Association Joins CNN iReport
10. China Diagnostic Reagent Industry Report, 2013-2016
11. Researchmoz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... HQ office, which includes executive, engineering and manufacturing functions to The LaunchPort™ Accelerator ... The Factory™, provide a full range of manufacturing and business services to its ...
(Date:9/21/2017)... Jersey (PRWEB) , ... September 21, 2017 , ... ... pharmaceutical and clinical research sector professionals, has announced the addition of 5 new ... 11 training - Compliance with Regulation 21 CFR Part 11 on Electronic ...
(Date:9/20/2017)... New Haven, CT (PRWEB) , ... September 20, ... ... therapeutics company, announced today that it has appointed Vishwas Paralkar to the role ... of Cybrexa’s tumor targeting technology. He will report to Cybrexa’s president and CEO, ...
(Date:9/20/2017)... ... September 20, 2017 , ... From industry leaders, sports stars, and Hollywood icons ... Many of these people had lost all hope. Their stories are told ... (pdf) , “Neil takes readers on a riveting journey through the past, ...
Breaking Biology Technology:
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
Breaking Biology News(10 mins):